Proteomic analysis of Alzheimer’s disease cerebrospinal fluid reveals alterations associated with APOE ε4 and atomoxetine treatment
Open accessThe DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
Abstract
Alzheimer’s disease (AD) is currently defined by the aggregation of amyloid-β (Aβ) and tau proteins in the brain. Although biofluid biomarkers are available to measure Aβ and tau pathology, few markers are available to measure the complex pathophysiology that is associated with these two cardinal neuropathologies. Here, we characterized the proteomic landscape of cerebrospinal fluid (CSF) changes associated with Aβ and tau pathology in 300 individuals using two different proteomic technologies—tandem mass tag mass spectrometry and SomaScan. Integration of both data types allowed for generation of a robust protein coexpression network consisting of 34 modules derived from 5242 protein measurements, including disease-relevant modules associated with autophagy, ubiquitination, endocytosis, and glycolysis. Three modules strongly associated with the apolipoprotein E ε4 ( APOE ε4) AD risk genotype mapped to oxidant detoxification, mitogen-associated protein kinase signaling, neddylation, and mitochondrial biology and overlapped with a previously described lipoprotein module in serum. Alterations of all three modules in blood were associated with dementia more than 20 years before diagnosis. Analysis of CSF samples from an AD phase 2 clinical trial of atomoxetine (ATX) demonstrated that abnormal elevations in the glycolysis CSF module—the network module most strongly correlated to cognitive function—were reduced by ATX treatment. Clustering of individuals based on their CSF proteomic profiles revealed heterogeneity of pathological changes not fully reflected by Aβ and tau.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
NIA‐AA Research Framework: Toward a biological definition of Alzheimer's disease
Jack, C. R., Bennett, D. A., Blennow, K., Carrillo, M. C., Dunn, B., Haeberlein, S. B., Holtzman, D. M., Jagust, W., Jessen, F., Karlawish, J., et al. (2018) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.02.018 · Cited by 10,537
Leek, J. T., Johnson, W. E., Parker, H. S., Jaffe, A. E., & Storey, J. D. (2012) · Bioinformatics · doi:10.1093/bioinformatics/bts034 · Cited by 6,231
Next-generation genotype imputation service and methods
Das, S., Forer, L., Schönherr, S., Sidore, C., Locke, A. E., Kwong, A., Vrieze, S. I., Chew, E. Y., Levy, S., McGue, M., et al. (2016) · Nature Genetics · doi:10.1038/ng.3656 · Cited by 3,808
Genome-wide efficient mixed-model analysis for association studies
Zhou, X., & Stephens, M. (2012) · Nature Genetics · doi:10.1038/ng.2310 · Cited by 3,627
Stages of the Pathologic Process in Alzheimer Disease: Age Categories From 1 to 100 Years
Braak, H., Thal, D. R., Ghebremedhin, E., & Del Tredici, K. (2011) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e318232a379 · Cited by 2,194 · cited 1×
“Norepinephrine tone in the brain is decreased in AD through dysfunction of the locus coeruleus, one of the first brain structures affected in AD ( 31 , 32 ).”
BackgroundCerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects
Shaw, L. M., Vanderstichele, H., Knapik‐Czajka, M., Clark, C. M., Aisen, P. S., Petersen, R. C., Blennow, K., Soares, H., Simon, A., Lewczuk, P., et al. (2009) · Annals of Neurology · doi:10.1002/ana.21610 · Cited by 2,065
Reimand, J., Isserlin, R., Voisin, V., Kucera, M., Tannus-Lopes, C., Rostamianfar, A., Wadi, L., Meyer, M., Wong, J., Xu, C., et al. (2019) · Nature Protocols · doi:10.1038/s41596-018-0103-9 · Cited by 1,970
Aptamer-Based Multiplexed Proteomic Technology for Biomarker Discovery
Gold, L., Ayers, D., Bertino, J., Bock, C., Bock, A., Brody, E. N., Carter, J., Dalby, A. B., Eaton, B. E., Fitzwater, T., et al. (2010) · PLoS ONE · doi:10.1371/journal.pone.0015004 · Cited by 1,754
A Cellular Perspective on Brain Energy Metabolism and Functional Imaging
Magistretti, P. J., & Allaman, I. (2015) · Neuron · doi:10.1016/j.neuron.2015.03.035 · Cited by 1,285
Johnson, E. C. B., Dammer, E. B., Duong, D. M., Ping, L., Zhou, M., Yin, L., Higginbotham, L. A., Guajardo, A., White, B., Troncoso, J. C., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0815-6 · Cited by 1,001
Self-citationFunctional brain abnormalities in young adults at genetic risk for late-onset Alzheimer's dementia
Reiman, E. M., Chen, K., Alexander, G. E., Caselli, R. J., Bandy, D., Osborne, D., Saunders, A. M., & Hardy, J. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2635903100 · Cited by 977 · cited 1×
“It has previously been shown that APOE ε 4 is associated with reduced brain metabolic function in early and midlife ( 40 , 41 ).”
BackgroundThe pathological process underlying Alzheimer’s disease in individuals under thirty
Braak, H., & Del Tredici, K. (2011) · Acta Neuropathologica · doi:10.1007/s00401-010-0789-4 · Cited by 812 · cited 1×
“Norepinephrine tone in the brain is decreased in AD through dysfunction of the locus coeruleus, one of the first brain structures affected in AD ( 31 , 32 ).”
BackgroundThe amyloid hypothesis in Alzheimer disease: new insights from new therapeutics
Karran, E., & De Strooper, B. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00391-w · Cited by 742
Improved discrimination of AD patients using β-amyloid (1-42) and tau levels in CSF
Hulstaert, F., Blennow, K., Ivanoiu, A., Schoonderwaldt, H. C., Riemenschneider, M., Deyn, P. P. D., Bancher, C., Cras, P., Wiltfang, J., Mehta, P. D., et al. (1999) · Neurology · doi:10.1212/wnl.52.8.1555 · Cited by 724 · cited 1×
“ELISA values were used to support diagnostic classification based on established AD biomarker cutoff criteria ( 46 , 47 ).”
MethodCo-regulatory networks of human serum proteins link genetics to disease
Emilsson, V., Ilkov, M., Lamb, J. R., Finkel, N., Gudmundsson, E. F., Pitts, R., Hoover, H., Gudmundsdottir, V., Horman, S. R., Aspelund, T., et al. (2018) · Science · doi:10.1126/science.aaq1327 · Cited by 680
Self-citationthe Dominantly Inherited Alzheimer Network, Barthélemy, N. R., Li, Y., Joseph-Mathurin, N., Gordon, B. A., Hassenstab, J., Benzinger, T. L. S., Buckles, V., Fagan, A. M., Perrin, R. J., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0781-z · Cited by 651
Age, Gene/Environment Susceptibility-Reykjavik Study: multidisciplinary applied phenomics
Harris, T. B., Launer, L. J., Eiriksdottir, G., Kjartansson, O., Jonsson, P. V., Sigurdsson, G., Thorgeirsson, G., Aspelund, T., Garcia, M. E., Cotch, M. F., et al. (2007) · American Journal of Epidemiology · doi:10.1093/aje/kwk115 · Cited by 592
Self-citationJohnson, E. C. B., Carter, E. K., Dammer, E. B., Duong, D. M., Gerasimov, E. S., Liu, Y., Liu, J., Betarbet, R., Ping, L., Yin, L., et al. (2022) · Nature Neuroscience · doi:10.1038/s41593-021-00999-y · Cited by 561
Self-citationCSF A β 42/A β 40 and A β 42/A β 38 ratios: better diagnostic markers of Alzheimer disease
Janelidze, S., Zetterberg, H., Mattsson, N., Palmqvist, S., Vanderstichele, H., Lindberg, O., van Westen, D., Stomrud, E., Minthon, L., Blennow, K., et al. (2016) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.274 · Cited by 456
Fueling thought: Management of glycolysis and oxidative phosphorylation in neuronal metabolism
Yellen, G. (2018) · Journal of Cell Biology · doi:10.1083/jcb.201803152 · Cited by 371 · cited 1×
“Alternatively, it could represent a metabolic shift in neurons from constitutive aerobic metabolism to glycolytic metabolism as part of a stress response ( 37 , 38 ).”
BackgroundHigginbotham, L., Ping, L., Dammer, E. B., Duong, D. M., Zhou, M., Gearing, M., Hurst, C., Glass, J. D., Factor, S. A., Johnson, E. C. B., et al. (2020) · Science Advances · doi:10.1126/sciadv.aaz9360 · Cited by 367
Self-citationHigginbotham, L., Ping, L., Dammer, E. B., Duong, D. M., Zhou, M., Gearing, M., Johnson, E. C. B., Hajjar, I., Lah, J. J., Levey, A. I., et al. (2019) · doi:10.1101/806752 · Cited by 367
Self-citationChang, S., Ma, T. R., Miranda, R. D., Balestra, M. E., Mahley, R. W., & Huang, Y. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0508254102 · Cited by 319
Yang, C., Farias, F. H. G., Ibanez, L., Suhy, A., Sadler, B., Fernandez, M. V., Wang, F., Bradley, J. L., Eiffert, B., Bahena, J. A., et al. (2021) · Nature Neuroscience · doi:10.1038/s41593-021-00886-6 · Cited by 290
Self-citationProteome profiling in cerebrospinal fluid reveals novel biomarkers of Alzheimer's disease
Bader, J. M., Geyer, P. E., Müller, J. B., Strauss, M. T., Koch, M., Leypoldt, F., Koertvelyessy, P., Bittner, D., Schipke, C. G., Incesoy, E. I., et al. (2020) · Molecular Systems Biology · doi:10.15252/msb.20199356 · Cited by 286 · cited 1×
“Proteomic analysis of AD CSF to assess disease-associated changes has most commonly been performed using unbiased mass spectrometry (MS)–based approaches and has led to a common set of robust changes observed across multiple studies ( 6 , 10 – 14 ).”
MethodMultiplex proteomics identifies novel CSF and plasma biomarkers of early Alzheimer’s disease
Whelan, C. D., Mattsson, N., Nagle, M. W., Vijayaraghavan, S., Hyde, C., Janelidze, S., Stomrud, E., Lee, J., Fitz, L., Samad, T. A., et al. (2019) · Acta Neuropathologica Communications · doi:10.1186/s40478-019-0795-2 · Cited by 262
Wang, H., Dey, K. K., Chen, P.-C., Li, Y., Niu, M., Cho, J.-H., Wang, X., Bai, B., Jiao, Y., Chepyala, S. R., et al. (2020) · Molecular Neurodegeneration · doi:10.1186/s13024-020-00384-6 · Cited by 243
Rorabaugh, J. M., Chalermpalanupap, T., Botz-Zapp, C. A., Fu, V. M., Lembeck, N. A., Cohen, R. M., & Weinshenker, D. (2017) · Brain · doi:10.1093/brain/awx232 · Cited by 227 · cited 1×
“Increasing brain norepinephrine has positive effects in preclinical AD models ( 33 ) and had a beneficial effect on CSF tTau and pTau181 and brain metabolic function as assessed by [ 18 F]fluorodeoxyglucose positron emission tomography (PET) after 6 months of ATX treatment in the phase 2 clinical…”
MethodCerebrospinal fluid proteomics define the natural history of autosomal dominant Alzheimer’s disease
Johnson, E. C. B., Bian, S., Haque, R. U., Carter, E. K., Watson, C. M., Gordon, B. A., Ping, L., Duong, D. M., Epstein, M. P., McDade, E., et al. (2023) · Nature Medicine · doi:10.1038/s41591-023-02476-4 · Cited by 170 · cited 2×
“These two possibilities are not mutually exclusive; longitudinal studies in ADAD have suggested that there may be two distinct phases of metabolic changes during the evolution of AD pathology ( 35 ).”
BackgroundSelf-citationWalker, K. A., Chen, J., Shi, L., Yang, Y., Fornage, M., Zhou, L., Schlosser, P., Surapaneni, A., Grams, M. E., Duggan, M. R., et al. (2023) · Science Translational Medicine · doi:10.1126/scitranslmed.adf5681 · Cited by 148 · cited 1×
“…factor 15 (GDF15) that have no known expression in the brain have been associated with all-cause dementia up to 25 years later ( 44 ), highlighting the possibility that the APOE ε 4–associated modules observed in this study may simply reflect a systemic process observable in…”
BackgroundSelf-citationCruchaga, C., Western, D., Timsina, J., Wang, L., Wang, C., Yang, C., Ali, M., Beric, A., Gorijala, P., Kohlfeld, P., et al. (2023) · doi:10.21203/rs.3.rs-2814616/v1 · Cited by 112 · cited 1×
“S2C) ( 21 ).”
Self-citationWestern, D., Timsina, J., Wang, L., Wang, C., Yang, C., Phillips, B., Wang, Y., Liu, M., Ali, M., Beric, A., et al. (2024) · Nature Genetics · doi:10.1038/s41588-024-01972-8 · Cited by 111
Self-citationTin, A., Yu, B., Ma, J., Masushita, K., Daya, N., Hoogeveen, R. C., Ballantyne, C. M., Couper, D., Rebholz, C. M., Grams, M. E., et al. (2019) · The Journal of Applied Laboratory Medicine · doi:10.1373/jalm.2018.027086 · Cited by 106
Alzheimer disease pathology and the cerebrospinal fluid proteome
Dayon, L., Núñez Galindo, A., Wojcik, J., Cominetti, O., Corthésy, J., Oikonomidi, A., Henry, H., Kussmann, M., Migliavacca, E., Severin, I., et al. (2018) · Alzheimer's Research & Therapy · doi:10.1186/s13195-018-0397-4 · Cited by 101
Sung, Y. J., Yang, C., Norton, J., Johnson, M., Fagan, A., Bateman, R. J., Perrin, R. J., Morris, J. C., Farlow, M. R., Chhatwal, J. P., et al. (2023) · Science Translational Medicine · doi:10.1126/scitranslmed.abq5923 · Cited by 84
Self-citationBatch correction and harmonization of –Omics datasets with a tunable median polish of ratio
Dammer, E. B., Seyfried, N. T., & Johnson, E. C. B. (2023) · Frontiers in Systems Biology · doi:10.3389/fsysb.2023.1092341 · Cited by 53
Self-citationTijms, B. M., Vromen, E. M., Mjaavatten, O., Holstege, H., Reus, L. M., van der Lee, S., Wesenhagen, K. E., Lorenzini, L., Vermunt, L., Venkatraghavan, V., et al. (2023) · doi:10.1101/2023.05.10.23289793 · Cited by 10
Cited by
Ali, M., Timsina, J., Western, D., Liu, M., Beric, A., Budde, J., Do, A., Heo, G., Wang, L., Gentsch, J., et al. (2025) · Neuron · doi:10.1016/j.neuron.2025.02.014 · Cited by 61
Self-citationLizama, B. N., Williams, C., North, H. A., Pandey, K., Duong, D., Di Caro, V., Mecca, A. P., Blennow, K., Zetterberg, H., Levey, A. I., et al. (2024) · Alzheimer's & Dementia · doi:10.1002/alz.14152 · Cited by 8
Self-citationSoluble CSF1R promotes microglial activation and amyloid clearance in Alzheimer’s disease
Zhang, L., Chen, K., Zeng, R., Bu, G., & Chen, X.-F. (2025) · Journal of Neuroinflammation · doi:10.1186/s12974-025-03558-5 · Cited by 7
Serum proteomics reveals APOE dependent and independent protein signatures in Alzheimer’s disease
Frick, E. A., Emilsson, V., Jonmundsson, T., Steindorsdottir, A. E., Johnson, E. C. B., Puerta, R., Dammer, E. B., Shantaraman, A., Cano, A., Boada, M., et al. (2023) · doi:10.1101/2023.11.08.23298251 · Cited by 3
Self-citation
Metadata
- Authors
- Dammer, E. B., Shantaraman, A., Ping, L., Duong, D. M., Gerasimov, E. S., Ravindran, S. P., Gudmundsdottir, V., Frick, E. A., Gomez, G. T., Walker, K. A., Emilsson, V., Jennings, L. L., Gudnason, V., Western, D., Cruchaga, C., Lah, J. J., Wingo, T. S., Wingo, A. P., Seyfried, N. T., Levey, A. I., & Johnson, E. C. B.
- Venue
- Science Translational Medicine
- Published
- 2024-06-26
- Volume
- 16
- Issue
- 753
- Pages
- eadn3504-eadn3504
- ISSN
- 1946-6234 (ISSN-L)
- 1946-6242
- OpenAlex
- W4400034124
- Cited by
- 54
- References
- 37
- FWCI
- 12.54
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.